Pimecrolimus (Elidel, SDZ ASM 981) - Preclinical pharmacologic profile and skin selectivity

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 4, 2001, Pages 233-241

  Stuetz, A ^a   Grassberger, M ^a   Meingassner, J G ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; CLOBETASOL; CYCLOSPORIN A; LACTAM DERIVATIVE; PIMECROLIMUS; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DERMATITIS; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; HUMAN; MAST CELL; MEDIATOR RELEASE; NONHUMAN; PSORIASIS; SKIN ATROPHY; T LYMPHOCYTE;

EID: 0035211722     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.29066     Document Type: Article

References (31)

1. Immunophilins as drug targets
2. Ascomycins
3. Ascomycins: Promising agents for the treatment of inflammatory skin diseases
4. Ascomycin, an antifungal antibiotic
5. Clearing of psoriasis by a novel immunosuppressive macrolide
6. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
7. First experience of topical SDZ ASM 981 in children with atopic dermatitis
8. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
9. SDZ ASM 981 cream 1% is efficacious and safe in infants aged 3-23 months with atopic dermatitis
10. SDZ ASM 981: A new approach to long-term management of atopic dermatitis in children
11. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomised, double-blind controlled study
12. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions
13. SDZ ASM 981: Pharmacokinetics in adults and children
14. Consistently low blood levels of pimecrolimus (Elidel, SDZ ASM 981) after occlusive treatment at chronic hand dermatitis
15. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge
16. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
17. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis
18. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
19. SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells
20. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
21. The ascomycin macrolactam pimecrolimus (Elidel®, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
22. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
23. SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis
24. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
25. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506
26. Pimecrolimus (Elidel®, SDZ ASM 981): Highly effective in models of skin inflammation but low activity in models of immunosuppression
27. Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis
28. Immunosuppressive macrolides of the type FK506: A novel class of topical agents for treatment of skin diseases
29. Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in Göttingen Minipigs
30. Comparison of human skin or epidermis models with human and animal skin in-vitro percutaneous absorption
31. Gene profiling of blood cells from psoriatic patients after oral treatment with SDZ ASM 981